That's awe_老虎社区_美港股上老虎

2021-12-01

That's awesome!! Let's be positive that FDA will give its approval.. 😁

FDA advisers recommend Merck's COVID-19 pill in close vote

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609483017,"tweetId":"609483017","gmtCreate":1638317563492,"gmtModify":1638317564846,"author":{"id":4099402595795420,"idStr":"4099402595795420","authorId":4099402595795420,"authorIdStr":"4099402595795420","name":"Nayazindagi","avatar":"https://static.tigerbbs.com/491906a0e23ae13ce2be00cf4d568603","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>That's awesome!!&nbsp; Let's be positive that FDA will give its approval.. 😁</p></body></html>","htmlText":"<html><head></head><body><p>That's awesome!!&nbsp; Let's be positive that FDA will give its approval.. 😁</p></body></html>","text":"That's awesome!! Let's be positive that FDA will give its approval.. 😁","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609483017","repostId":2188787534,"repostType":2,"repost":{"id":"2188787534","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638315540,"share":"https://www.laohu8.com/m/news/2188787534?lang=&edition=full","pubTime":"2021-12-01 07:39","market":"us","language":"en","title":"FDA advisers recommend Merck's COVID-19 pill in close vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2188787534","media":"Dow Jones","summary":"If molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the f","content":"<p>If molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the first oral COVID-19 pill you can take at home</p>\n<p>The Food and Drug Administration advisory committee said the benefits of Merck's experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> were up nearly 1% in after-hours trading on Tuesday. The company is developing the pill, which is called molnupiravir, with the privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the first oral COVID-19 pill during the pandemic that you can take at home.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA advisers recommend Merck's COVID-19 pill in close vote</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA advisers recommend Merck's COVID-19 pill in close vote\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-01 07:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the first oral COVID-19 pill you can take at home</p>\n<p>The Food and Drug Administration advisory committee said the benefits of Merck's experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> were up nearly 1% in after-hours trading on Tuesday. The company is developing the pill, which is called molnupiravir, with the privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the first oral COVID-19 pill during the pandemic that you can take at home.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4516":"特朗普概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188787534","content_text":"If molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the first oral COVID-19 pill you can take at home\nThe Food and Drug Administration advisory committee said the benefits of Merck's experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.\nShares of Merck & Co. Inc. $(MRK)$ were up nearly 1% in after-hours trading on Tuesday. The company is developing the pill, which is called molnupiravir, with the privately held Ridgeback Biotherapeutics.\nThe FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.\nIf molnupiravir is authorized by the FDA in the coming weeks, as has been expected, it will be the first oral COVID-19 pill during the pandemic that you can take at home.","news_type":1},"isVote":1,"tweetType":1,"viewCount":829,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":60,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609483017"}